Karen L. Abbott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karen L. Abbott has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Blake P. Johnson
Ouachita Baptist University, Department of Biology, Arkadelphia, USA
2 shared publications- Heba Allam
Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA
2 shared publications Zhongpeng Lu
University of Arkansas for Medical Sciences, Department of Biochemistry and Molecular Biology, Little Rock, USA
2 shared publications- Alison V. Nairn
Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA
1 shared publication Benedict B. Benigno
Ovarian Cancer Institute, 960 Johnson Ferry Road, Atlanta, Georgia 30342, United States
1 shared publicationCatherin C. Yin
SRI International Biosciences Division, Center for Cancer and Metabolism, Menlo Park, USA
1 shared publication
Latest Publications
- Open Access
- 25 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-11
Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms
Tumor-specific glycosylation changes are an attractive target for the development of diagnostic and therapeutic applications. Periostin is a glycoprotein with high expression in many tumors of epithelial origin including ovarian cancer. Strategies to target the peptide portion of periostin as a diagnostic or therapeutic biomarker for cancer are limited due to increased expression of periostin in non-cancerous inflammatory conditions. Here, we have screened for antibody fragments that recognize the tumor-specific glycosylation present on glycoforms of periostin containing bisecting N-glycans in ovarian cancer using a yeast-display library of antibody fragments, while subtracting those that bind to the periostin protein with glycoforms found in non-malignant cell types. We generated a biotinylated form of a fully human scFv antibody (scFvC9) that targets the bisecting N-glycans expressed by cancer cells. Validation studies in vitro and in vivo using scFvC9 indicate this antibody can be useful for the development of diagnostic, imaging, and therapeutic applications for cancers that express the antigen.
- 25 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-11
Open AccessGeneration of a Fully Human scFv that binds Tumor-Specific Glycoforms
Tumor-specific glycosylation changes are an attractive target for the development of diagnostic and therapeutic applications. Periostin is a glycoprotein with high expression in many tumors of epithelial origin including ovarian cancer. Strategies to target the peptide portion of periostin as a diagnostic or therapeutic biomarker for cancer are limited due to increased expression of periostin in non-cancerous inflammatory conditions. Here, we have screened for antibody fragments that recognize the tumor-specific glycosylation present on glycoforms of periostin containing bisecting N-glycans in ovarian cancer using a yeast-display library of antibody fragments, while subtracting those that bind to the periostin protein with glycoforms found in non-malignant cell types. We generated a biotinylated form of a fully human scFv antibody (scFvC9) that targets the bisecting N-glycans expressed by cancer cells. Validation studies in vitro and in vivo using scFvC9 indicate this antibody can be useful for the development of diagnostic, imaging, and therapeutic applications for cancers that express the antigen.
- Open Access
- 1 September 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (39) , 16351-16359
The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer
- 1 September 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (39) , 16351-16359
Open AccessThe glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer
- 1 January 2015
- Published by Elsevier
- Vol. 126, 281-303
Functional Impact of Tumor-Specific N-Linked Glycan Changes in Breast and Ovarian Cancers
- 1 January 2015
- Published by Elsevier
- Vol. 126, 281-303
Functional Impact of Tumor-Specific N-Linked Glycan Changes in Breast and Ovarian Cancers
- Open Access
- 1 December 2014
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 14 (1) , 434-446
Glycomic Analysis of Membrane Glycoproteins with Bisecting Glycosylation from Ovarian Cancer Tissues Reveals Novel Structures and Functions
Biomarkers capable of detecting and targeting epithelial ovarian cancer cells for diagnostics and therapeutics would be extremely valuable. Ovarian cancer is the deadliest reproductive malignancy among women in the U.S., killing over 14 000 women each year. Both the lack of presenting symptoms and high mortality rates illustrate the need for earlier diagnosis and improved treatment of this disease. The glycosyltransferase enzyme GnT-III encoded by the Mgat3 gene is responsible for the addition of GlcNAc (N-acetylglucosamine) to form bisecting N-linked glycan structures. GnT-III mRNA expression is amplified in ovarian cancer tissues compared with normal ovarian tissue. We use a lectin capture strategy coupled to nano-ESI–RPLC–MS/MS to isolate and identify the membrane glycoproteins and unique glycan structures associated with GnT-III amplification in human ovarian cancer tissues. Our data illustrate that the majority of membrane glycoproteins with bisecting glycosylation are common to both serous and endometrioid histological subtypes of ovarian cancer, and several have been reported to participate in signaling pathways such as Notch, Wnt, and TGFβ.
- 1 December 2014
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 14 (1) , 434-446
Open AccessGlycomic Analysis of Membrane Glycoproteins with Bisecting Glycosylation from Ovarian Cancer Tissues Reveals Novel Structures and Functions
Biomarkers capable of detecting and targeting epithelial ovarian cancer cells for diagnostics and therapeutics would be extremely valuable. Ovarian cancer is the deadliest reproductive malignancy among women in the U.S., killing over 14 000 women each year. Both the lack of presenting symptoms and high mortality rates illustrate the need for earlier diagnosis and improved treatment of this disease. The glycosyltransferase enzyme GnT-III encoded by the Mgat3 gene is responsible for the addition of GlcNAc (N-acetylglucosamine) to form bisecting N-linked glycan structures. GnT-III mRNA expression is amplified in ovarian cancer tissues compared with normal ovarian tissue. We use a lectin capture strategy coupled to nano-ESI–RPLC–MS/MS to isolate and identify the membrane glycoproteins and unique glycan structures associated with GnT-III amplification in human ovarian cancer tissues. Our data illustrate that the majority of membrane glycoproteins with bisecting glycosylation are common to both serous and endometrioid histological subtypes of ovarian cancer, and several have been reported to participate in signaling pathways such as Notch, Wnt, and TGFβ.
- 27 February 2014
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 14 (1) , 55-62
Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin
The glycosylphosphatidylinositol (GPI) anchor is a glycan and lipid posttranslational modification added to proteins in the endoplasmic reticulum. Certain enzymes within the GPI biosynthetic pathway, particularly the subunits of the GPI transamidase,
- 27 February 2014
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 14 (1) , 55-62
Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin
The glycosylphosphatidylinositol (GPI) anchor is a glycan and lipid posttranslational modification added to proteins in the endoplasmic reticulum. Certain enzymes within the GPI biosynthetic pathway, particularly the subunits of the GPI transamidase,